NEW

Altapure’s Technology Achieves High Level Disinfection of N95 Safety Masks

Altapure, LLC, an innovative technology and manufacturing company dedicated to providing high-level disinfection products to medical and long-term care facilities, today announced new data evaluating two of its devices for the disinfection of personal protective...

MediCapture Launches TRS Pro Wireless Medical Tablet Recorder System

MediCapture announced that it is launching the TRS Pro, a new and convenient approach to how surgeries are recorded and managed. The first of its kind, TRS Pro comes with MediCapture’s advanced MVR medical video recorder and a wireless tablet that can be connected to...

Agreement Brings NomoLine Capnography, O3 Regional Oximetry to Select Patient Monitors

Masimo and Royal Philips announced that they have reinforced their partnership, whereby Philips will integrate additional Masimo measurement technologies into select IntelliVue MX-series multi-parameter monitors, to help clinicians assess cerebral oximetry and...

FDA Letter: Use Correct Cycle When Decontaminating Respirators with STERRAD Sterilization Systems

The U.S. Food and Drug Administration (FDA) reminds reprocessing staff in health care facilities to use the correct decontamination cycle associated with certain models of the Advanced Sterilization Products (ASP) STERRAD Sterilization Systems and to only...

BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease

BD (Becton, Dickinson and Company), a global medical technology company, has announced the U.S. Food and Drug Administration has granted premarket approval for the Venovo™ venous stent, the first stent indicated to treat iliofemoral venous occlusive disease, which is obstructed or narrowed blood flow specific to the iliac and femoral veins located near the groin.

The Venovo™ venous stent is a flexible nitinol stent specifically designed to reopen blocked iliac and femoral veins in order to maintain adequate blood flow. The Venovo™ venous stent is designed with a balance of radial strength, compression resistance and flexibility needed for the treatment of symptomatic post-thrombotic and non-thrombotic iliofemoral lesions. Additionally, the broad stent sizing allows clinicians to treat large diameter veins and long lesion lengths.

“The unique attributes of the Venovo stent make it particularly well-suited to treat iliofemoral occlusive disease,” said Dr. Michael Dake, University of Arizona and the principal investigator for the Venovo IDE trial. “Most importantly, it is purpose-built for application in veins, and engineered to address the special challenges of venous lesions that are very different than those posed by arterial narrowing.”

Iliofemoral venous occlusive disease occurs when there is impaired blood flow in the iliofemoral vein caused by acute or chronic deep-vein thrombosis, post-thrombotic syndrome, iliofemoral vein compression including May-Thurner Syndrome or a combination of these diseases.[1] Symptoms include swelling of the legs, pain when standing, skin discoloration and ulcers.[2]

One-year results from the prospective, multicenter single-arm VERNACULAR trial involving 170 subjects demonstrated the safety and effectiveness of the Venovo™ venous stent for the treatment of symptomatic iliofemoral venous outflow obstruction. The clinical findings showed a weighted primary patency rate of 88.3 percent, with a 96.9 percent patency rate in non-thrombotic lesions and an 81.3 percent patency rate in post-thrombotic lesions at 12 months, exceeding the performance goal of 74 percent. In addition, patients treated with the Venovo™ venous stent reported a statistically significant reduction in pain symptoms and improvement in quality of life (assessed by CIVIQ-20) at 12 months from baseline. The Venovo™ venous stent was also deployed successfully to the target lesion and showed adequate coverage in all cases, and there were no fractures seen at 12 months.

“The FDA premarket approval of the Venovo venous stent represents a significant advance for interventionalists treating iliofemoral venous occlusive disease, an underrecognized condition,” said Steve Williamson, worldwide president of Peripheral Intervention at BD. “We designed the Venovo venous stent in collaboration with clinicians to enable them to treat both post-thrombotic and non-thrombotic lesions. Clinicians will now have access to the broadest range of stent sizes in the U.S. for these difficult-to-treat lesions.”

The Venovo™ venous stent is commercially available in the U.S., Europe, Argentina, Australia, Brazil, Egypt, India, Israel, Mexico, Russia, Saudi Arabia, Singapore and Taiwan.

For more information on BD, please visit bd.com.


1. Foley T, et al. (2015). Iliofemoral Deep Vein Thrombosis, Available online 24 November 2015.
2. Al-Nouri O, Milner R. May-Thurner Syndrome, Vascular Disease Management 2011; 8(3).

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X